Floatz logo

Fruquintinib

Advanced Renal Cell Carcinoma

Sun Yat-sen UniversitySmall moleculePhase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

297 Active assets in the Advanced Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
INTERFERON-ALFA-2A
Central European Society for Anticancer Drug Research
Phase 3BB

View all 50 →

Same molecule, other indications

Fruquintinib is also rated in:

metastasis from malignant tumor of colonDormant
BBB
Indicative ·
72 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →